AAminove
Back to library

Tirzepatide

Human RCTApproved medicine

Also known as: Mounjaro, Zepbound

GLP-1 / incretinType 2 diabetesWeight management

Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.

Overview

A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and weight management, with strong randomised-trial evidence.

Mechanism

Activates both GIP and GLP-1 receptors, improving insulin secretion and sensitivity while reducing appetite and slowing gastric emptying.

Evidence

Human RCTWhat does this mean?

Strong: SURPASS and SURMOUNT phase 3 RCT programmes and regulatory approval.

Community-reported information

A prescription medicine dosed per the approved label and a clinician. This app does not restate a personalised schedule.

General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.

Half-life

~5 days (once-weekly dosing)

Storage

Refrigerate 2–8 °C per label.

Commonly reported side effects

  • Nausea
  • Diarrhoea
  • Decreased appetite
  • Vomiting
  • Constipation

Legal status by region

  • USFDA-approved prescription medicine.
  • GBMHRA-licensed; prescription only.
  • AUTGA-registered; prescription only (Schedule 4).

Legal status changes over time; verify locally before relying on this.

Citations